CD274 and non-small cell lung carcinoma: Although both PD-1/PD-L1 inhibitor monotherapy and chemoimmunotherapy are effective first-line treatment regimens for PD-L1 high NSCLC patients, several systematic reviews have suggested that chemoimmunotherapy may be more effective under certain conditions (1, 2).